Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder, which results from the loss of specific population of neurons, namely the pigmented dopamine secreting neurons of the substnatia nigra pars compatica (SNPc) of midbrain. The exact cause leading to nigrostriatal cell death is not yet known. In recent years, accumulating evidence from the identified molecular events in familial forms of PD contributed much to unraveling the mechanisms by which dopaminergic neurons die in PD and which hopefully would lead to the development of therapeutic interventions. Several major disease causing pathways were identified so far. These are possibly interconnected and some genes share a common pathway e.g., (i) defects in ubiquitin-proteasome pathway and protein misfolding and aggregation caused by α-synuclein and Parkin gene defects; (ii) defects in mitochondrial morphology and function in PINK1/Parkin and DJ-1 mutations; (iii) increased susceptibility to cellular oxidative stress which appear to underlie defects in α-synuclein, Parkin and DJ-1 genes. The aim of this review is to shed light on the molecular mechanisms by which mutations in familial-linked genes cause PD.
Keywords: Genetic studies, mitochondria, Parkinson’s disease (PD), oxidative stress, ubiquitin-proteasome pathway.
CNS & Neurological Disorders - Drug Targets
Title:The Paths to Neurodegeneration in Genetic Parkinson's Disease
Volume: 13 Issue: 9
Author(s): Omar M.E. Abdel-Salam
Affiliation:
Keywords: Genetic studies, mitochondria, Parkinson’s disease (PD), oxidative stress, ubiquitin-proteasome pathway.
Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder, which results from the loss of specific population of neurons, namely the pigmented dopamine secreting neurons of the substnatia nigra pars compatica (SNPc) of midbrain. The exact cause leading to nigrostriatal cell death is not yet known. In recent years, accumulating evidence from the identified molecular events in familial forms of PD contributed much to unraveling the mechanisms by which dopaminergic neurons die in PD and which hopefully would lead to the development of therapeutic interventions. Several major disease causing pathways were identified so far. These are possibly interconnected and some genes share a common pathway e.g., (i) defects in ubiquitin-proteasome pathway and protein misfolding and aggregation caused by α-synuclein and Parkin gene defects; (ii) defects in mitochondrial morphology and function in PINK1/Parkin and DJ-1 mutations; (iii) increased susceptibility to cellular oxidative stress which appear to underlie defects in α-synuclein, Parkin and DJ-1 genes. The aim of this review is to shed light on the molecular mechanisms by which mutations in familial-linked genes cause PD.
Export Options
About this article
Cite this article as:
Abdel-Salam M.E. Omar, The Paths to Neurodegeneration in Genetic Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (9) . https://dx.doi.org/10.2174/1871527313666140806142955
DOI https://dx.doi.org/10.2174/1871527313666140806142955 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Syntheses of Amido-, Carbamido- and Carbamatoalkylnaphthols
Current Organic Synthesis Chemical Constituents and Biological Significance of the Genus Ilex (Aquifoliaceae)
The Natural Products Journal Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Immune Response Towards Snake Venoms
Inflammation & Allergy - Drug Targets (Discontinued) Reducing Perioperative Myocardial Infarction with Anesthetic Drugs and Techniques
Current Drug Targets Hypertension in Hemodialysis Patients
Current Hypertension Reviews Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling
Current Gene Therapy PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review
Current Pharmaceutical Design Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?
Current Neuropharmacology Statin Therapy
Current Pharmaceutical Design